Haemophilus influenzae type b vaccine
Out of the 72 countries currently eligible for GAVI support, 68 countries currently qualify for support for the introduction of haemophilus influenzae type b vaccine - meaning that their immunisation coverage for the third dose for diptheria, pertussis and tetanus (DTP3) has reached 50% and the government is not already funding the vaccine - GAVI conditions for Hib support.
As at January 2009, 58 of these 68 currently qualifying countries had had their applications approved, with 56 of them requesting support for the pentavalent formulation of the vaccine.
The increased long-term availability of pentavalent vaccine sparked a dramatic increase in the number of countries applying to GAVI for support for Hib in 2007 and 2008. Pentavalent's supply was partly secured by the Alliance directing a large amount of IFFIm-generated resources to it.
Data source: GAVI Alliance
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the GAVI Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not be full agreement.
Note: Between 2000 and 2005, 75 countries were eligible for GAVI support. In 2006, the list was updated according to the eligibility criteria: Albania, China, Bosnia and Herzegovina, and Turkmenistan were no longer eligible; Kiribati became eligible, making a total of 72 countries eligible for support from 2006.
 |
 |
 |